Herold Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Herold Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-50	Closed	-$4.69K	–	491
2022 Q1	$4.69K	Buy	+50	New	+$4.24K	﹤0.01%	677
2021 Q4	–	Sell	-150	Closed	-$14K	–	478
2021 Q3	$14K	Buy	+150	New	+$14.2K	0.01%	559

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Herold Advisors's NBIX Position: Q2 2022 in Review

Herold Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2022, closing a stake of 50 shares — an estimated $4.69K sold.

Herold Advisors first reported a position in NBIX in Q3 2021 and held it in 2 quarters. The position peaked at $14K in Q3 2021. 437 funds tracked by Wall St. Rank hold NBIX as of Q2 2022.

Herold Advisors reported no remaining Neurocrine Biosciences position as of Q2 2022 after selling out during the quarter.
Herold Advisors sold 50 Neurocrine Biosciences shares in Q2 2022, an estimated $4.69K.
Herold Advisors first reported a position in Neurocrine Biosciences in Q3 2021 and held it in 2 quarters.
Herold Advisors's Neurocrine Biosciences position peaked at $14K in Q3 2021.
437 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2022.

Based on Herold Advisors's 13F filing for Q2 2022, filed 15 Jul 2022.